Generating revenue of between $3m to $4.5m per month from stage 1 is encouraging.The prospect of the phes component earning an even greater return, should get investors interested.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025